Genetically Modified Kluyveromyces lactis as a Novel Therapeutic Approach for Inflammatory Bowel Disease

Abstract

Inflammatory bowel disease (IBD) is a chronic inflammatory disease of the gastrointestinal system that comprises Crohn’s disease (CD) and ulcerative colitis (UC). While several therapeutic approaches exist, many patients demonstrate limited therapeutic response or experience undesirable side effects, underscoring the necessity for novel treatment interventions. Current research highlights the function of the gut microbiome in IBD pathogenesis, indicating that microorganisms may have therapeutic capability. Kluyveromyces lactis is a yeast typically found in milk-derived products and recognized safe for humans. Due to its probiotic potential and compatibility for genetic modification, it may serve as a basis for designing new microbiome-based treatments. This study intends to investigate the anti-inflammatory properties of genetically modified Kluyveromyces lactis in murine experimental model of IBD and evaluate its potential as a new therapeutic approach.